This medicine is authorised for use in the European Union.


Ferriprox is an ‘iron chelator’ (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major. This is an inherited disease in which patients are unable to make enough haemoglobin, the protein found in red blood cells that carries oxygen around the body. 

Ferriprox is used:

  • on its own, when standard iron chelator treatment cannot be used or does not work well enough;
  • in combination with another iron chelator, when treatment with one iron chelator on its own does not work or when iron levels need to be rapidly or intensively corrected to prevent or treat life-threatening conditions (mainly affecting the heart). 

Ferriprox contains the active substance deferiprone.

This EPAR was last updated on 27/02/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • beta-Thalassemia
  • Iron Overload
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Chiesi Farmaceutici S.p.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Via Palermo 26/A
43122 Parma

Product information

30/09/2022 Ferriprox - EMEA/H/C/000236 - IB/0158

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

All other therapeutic products

Therapeutic indication

Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.

Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

Assessment history

How useful was this page?

Add your rating
1 rating